Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities
Getty Images
January 6, 2021 Hologic, Inc., a global leader in women s health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.
“Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion for women’s health,” said Kevin Thornal, Hologic’s Division President, Diagnostics. “Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to accelerate growth, he
Risk Disclaimer - By using this web site you agree to its terms and conditions.
All materials, including but not limited to articles, directories, photos, lists, etc., on this website are the sole property of ForexTV or the respective copyright holders and are intended for informational/educational purposes using hypothetical and sometimes anecdotal illustrations. The unauthorized use of any and all materials is prohibited and restricted by copyright law. Any use of materials on this site must be approved in advance by ForexTV.
Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any